Infrared-A (IR-A) Mediated Hyperthermia in the Treatment of Scleroderma-Associated Raynaud’s Phenomenon
Infrared-A (IR-A) Mediated Hyperthermia in the Treatment of Scleroderma-Associated Raynaud’s Phenomenon
Published: 2025-10-14 | Last Reviewed: 2025-10-14
1. Efficacy of Infrared-A Mediated Hyperthermia in Scleroderma-Associated Raynaud’s Phenomenon
Clinical research confirms that Whole-Body hyperthermia with wIRA radiation is an *effective method* for the treatment of *Raynaud’s Phenomenon (RP)* associated with *Systemic Sclerosis (Scleroderma)* [1]. By utilizing *Mild WB Hyperthermia (Mild wIR-A hyperthermia)*, the treatment targets the *vasoconstrictive symptoms* of RP, contributing to improved *microcirculation* and the management of the autoimmune skin and organ condition [2, 3]. These treatments represent an important *adjuvant therapy* in the complex management of scleroderma.
Mechanisms and Clinical Evidence
Clinical evidence regarding the use of Mild wIR-A Hyperthermia in Systemic Sclerosis (SS) and RP highlights the following:
- *Raynaud’s Phenomenon Treatment:* Specialized studies have demonstrated that *Infrared-A Mediated Hyperthermia* is effective in directly treating *Scleroderma-Associated Raynaud’s Phenomenon*, a critical component of the disease affecting peripheral circulation [1].
- *Systemic Sclerosis Amelioration:* Mild wIR-A Hyperthermia has been investigated as a treatment for *Systemic Sclerosis* itself, showing therapeutic potential in ameliorating symptoms and manifestations of the disease [3].
- *Controlled Technology:* Application is carried out using *computer-controlled wIR-A Hyperthermia*, which allows for precise and specific heat dosage to achieve optimal effect on affected tissues and microcirculation [2].
Frequently Asked Questions (FAQ)
Does Whole-Body Hyperthermia (WBH) treat Raynaud’s Phenomenon?
Yes. Studies show that *Infrared-A Mediated Hyperthermia* is effective in treating *Raynaud’s Phenomenon, especially when associated with **Systemic Sclerosis*, by combating vasoconstrictive symptoms [1].
What type of infrared is used for Scleroderma treatment?
*Mild water filtered Infrared-A radation WBH (wIR-A Hyperthermia)* is used, often computer-controlled, to ensure a safe and precise application in the treatment of symptoms associated with Systemic Sclerosis [2, 3].
How can the von Ardenne Iratherm 1000 Whole-Body Hyperthermia wIRA device be used for Scleroderma treatment ?
Overview of recommended WBH sessions with von Ardenne Iratherm 1000 WBH wIRA device and target temperatures – Treatments shall only be performed after final consultation with a medical doctor
| Indication | No. of sessions | Target temperature | Therapy time Increase phase Plateau phase | Rest time Resting phase | Total WBH session time | |
| Systemic Sclerosis | 15 | 38.3 °C | 30 min | 15 min | ~ 45 min | |
| 30 min | 0 min | |||||
Can Whole-Body Hyperthermia with wIRA be used for other pathologies?
Yes. Other benefits and areas of application of Whole Body Hyperthermia include Oncology, accelerated metabolism , stimulation of the hormonal system , reduction in muscle tone , enhanced nerve conduction, Systemic sclerosis, Depressive episode, Essential (primary) hypertension, Dorsalgia, Fibromyalgia, Ankylosing spondylitis
A more detailed list of studies and effects ( (from foundational studies on wIRA technology to crucial Phase III clinical trials) can be found here
von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-summary
Scientific References (E-E-A-T)
- Förster J., Fleischanderl S., Wittstock S., Storch A., Meffert H., Riemekasten G., Worm M.
Infrared-Mediated Hyperthermia is Effective in the Treatment of Scleroderma-Associated Raynaud’s Phenomenon.
J of Investigative Dermatology 2005; 6:1313-16 [pubmed] - Meffert B., Hochmuth O., Meffert H., Steiner M., Schmollak K, Buchholtz I.
Rechnergesteuerte Infrarot-A-Hyperthermie zur Behandlung der systemischen Sklerodermie.
ThermoMed 1992; 8:9-13 - Meffert H., Buchholtz I., Brenke A., Sönnichsen N.
Milde Infrarot-A-Hyperthermie zur Behandlung der systemischen Sklerodermie.
Dermatol Monatsschr 1990; 11:683-85
